HBsAg and HBV DNA quantification and diagnosis of HBV-related liver diseases

Abstract

Abstract: Objective To investigate the relationship of HBsAg and HBV DNA quantification and diagnosis of HBV-related liver diseases.Methods A total of 314 patients with HBsAg infection primary treated in the department of infection of the First People's Hospital of Yancheng from January 2021 to December 2022 were retrospectively analyzed. According to the clinical diagnosis, they were divided into four groups: chronic hepatitis B (CHB) group (group A, 141 cases), compensated hepatitis B cirrhosis group (group B, 48 cases), decompensated hepatitis B cirrhosis group (group C, 81 cases) and HBV-related liver cancer group (group D, 44 cases).The clinical and quantitative data of HBsAg, HBeAg and HBV DNA were analyzed retrospectively.Results In HBeAg-positive patients, there was a positive correlation between serum HBsAg quantification [(998.7± 944.2) IU/mL] and HBV DNA quantification [(5.4±2.1) lg IU/m] (r=0.294, P<0.001). In HBeAg-negative patients, there was a positive correlation between serum HBsAg quantification [(556.7±718.1)IU/mL] and HBV DNA quantification [(3.9±1.9) lg IU/mL] (r=0.173, P=0.035).The levels of HBsAg and HBV DNA in HBeAg positive patients were higher than those in HBeAg negative patients, and the difference was significant (P<0.05). In HBeAg positive patients, the quantitative levels of HBsAg [(1568.3±990.4、513.4±402.3、380.6±332.4、345.1±254.8)IU/mL]and HBV DNA[(6.0±2.3、5.3±1.6、4.6±1.7、4.5 ±1.7)lg IU/mL] showed a decreasing trend in groups A, B, C and D ( Kruskal-Wallis test showed progressive significance, P<0.05). In HBeAg-negative patients, the quantitative level of HBsAg[(855.9±119.3、497.9±625.0、329.1±452.0、305.1±407.4)IU/mL] in group A, B, C and D showed a decreasing trend (Kruskal-Wallis test showed gradual significance, P<0.05), and there was no significant difference in HBV DNA quantification [(4.3±2.0、3.5±1.8、3.6±1.6、3.8 ±1.7)lgIU/mL]among the four groups, and the correlation was not obvious (Kruskal-Wallis test showed no difference, P=0.242).Conclusion There is a significant positive correlation between HBsAg quantification and HBV DNA quantification, and gradually decreases with the severity of liver disease; while HBeAg is negative, there is no obvious correlation between HBV DNA quantification and the severity of liver disease.

Key words: Hepatitis B surface antigen, Hepatitis B virus deoxyribonucleic acid, Chronic hepatitis B, Diagnosis

XUE Rong-rong, CAI Bing-gang, XIAN Jian-chun. HBsAg and HBV DNA quantification and diagnosis of HBV-related liver diseases[J]. Chinese Hepatolgy, 2023, 28(12): 1462-1465.

References

[1] Global progress report on HIV, viral hepapatis and sexually transmitted infectionsinfections, 2021,Accountability for the global health sector strategies2016-2021: actions for impact[EB/OL]. https://apps.who.int/iris/bitstream/handle/10665/342808/9789240030985-eng.pdf.
[2] Zhao YJ, Ju Q, Li GC. Tumor markers for hepatocellular carcinoma[J]. Mol Clin Oncol, 2013, 1(4): 593-598.
[3] Hadziyannis E , Laras A, Viral Biomarkers in Chronic HBeAg Negative HBV Infection[J]. Genes(Base1), 2018, 9(10): 469.
[4] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2022, 15(6):401-427.
[5] Celik M,Arabul M,Ceki? C,et al. Clinical utility of hepatitis B surface antigen levels during the natural history and treatment of chronic hepatitis B infection[J]. Prz Gastroenterol, 2014,9(3):164-167.
[6] 王贵强,王福生,庄辉,等. 慢性乙型肝炎防治指南(2019年版)[J]. 肝脏,2019,24(12):1335-1356.
[7] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中华临床感染病杂志, 2019, 12(6): 401-428.
[8] Philippe JZ , Ashley ML , Interpretation of HBV Serologies[J]. Clin Liver Dis, 2021,25(4):689-709.
[9] 中华医学会肝病学分会基础医学与实验诊断协作组. 乙型肝炎病毒标志物临床应用专家共识[J]. 中华肝脏病杂志,2023,31(04): 389-400.
[10] 孙丹凤, 陆许贞, 谢新生,等. 慢性乙型肝炎及肝硬化患者乙型肝炎表面抗原及乙型肝炎病毒DNA定量检测的临床意义[J]. 中华危重症医学杂志(电子版), 2017, 10(03): 172-175.
[11] 郜玉峰, 邹桂舟, 叶珺, 等. HBsAg和HBV DNA定量水平与肝纤维化程度的关系[J]. 中华肝脏病杂志, 2015, 23(4): 254-257.
[12] Martinot-Peignoux M , Carvalho-Filho R , Lapalus M , et al . Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naive, e antigen-positive patients[J]. J Hepatol, 2013, 58(6): 1089–1095.
[13] 黄绍萍,卢水华,王介非,等. 聚乙二醇干扰素α-2a 治疗慢性乙型病毒性肝炎 HBsAg 转阴影响因素分析[J]. 中国实用内科杂志,2009,29(11):1044-1045.
[14] 邬喆斌, 曹红, 刘婷, 等. 慢性乙型肝炎不同肝纤维化分期的肝实质细胞体积所分摊的HBsAg表达变化[J].中华肝脏病杂志, 2012, 20(10):742-745.
[15] Alexopoulou A , Karayiannis P. HBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection[J]. World J Gastrorenterol, 2014, 20(24): 7644-7652.
[16] Ringelhan M, O'Connor T, Protzer U, et al.The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets[J]. J Pathol, 2015, 235(2): 355-367.
[17] Manesis EK, Papatheodoridis GV, Tiniakos DG, et al. Hepatitis B surface antigen: Relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B[J]. J Hepatol, 2011, 55(1):61-68.
[18] Ramakrishna B, Mukhopadhya A, Kurian G. Correlation of hepatocyte expression of hepatitis B viral antigens with histological activity and viral titer in chronic hepatitis B virus infection: an immunohistochemical study[J]. J Gastroenterol Hepatol, 2010, 23(11):1734-1738.
[19] 周文红, 应豪. 慢性乙型肝炎患者肝组织HBsAg、HBcAg表达及临床意义[J]. 中西医结合肝病杂志, 2006, 16(5) : 266-267.
[20] 陆伟, 张占卿, 张小楠, 等. 肝组织HBsAg、HBcAg和血清HBsAg水平、HBV DNA载量与肝组织病理学相关性[J]. 肝脏, 2014, 19(07) : 491-497+510.